224 related articles for article (PubMed ID: 26689970)
1. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
[TBL] [Abstract][Full Text] [Related]
2. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Raffi F; Orkin C; Clarke A; Slama L; Gallant J; Daar E; Henry K; Santana-Bagur J; Stein DK; Bellos N; Scarsella A; Yan M; Abram ME; Cheng A; Rhee MS
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):226-231. PubMed ID: 28272164
[TBL] [Abstract][Full Text] [Related]
4. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
[TBL] [Abstract][Full Text] [Related]
5. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Chirwa LI; Johnson JA; Niska RW; Segolodi TM; Henderson FL; Rose CE; Li JF; Thigpen MC; Matlhaba O; Paxton LA; Brooks JT
AIDS; 2014 Jan; 28(2):223-6. PubMed ID: 24361682
[TBL] [Abstract][Full Text] [Related]
6. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
[TBL] [Abstract][Full Text] [Related]
7. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
8. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Polo R; García-Albéniz X; Terán C; Morales M; Rial-Crestelo D; Garcinuño MA; García Del Toro M; Hita C; Gómez-Sirvent JL; Buzón L; Díaz de Santiago A; Arellano JP; Sanz J; Bachiller P; Alfaro EM; Díaz-Brito V; Masiá M; Hernández-Torres A; Guerra JM; Santos J; Arazo P; Muñoz L; Arribas JR; Martínez de Salazar P; Moreno S; Hernán MA; Del Amo J;
Clin Microbiol Infect; 2023 Jan; 29(1):85-93. PubMed ID: 35940567
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Grant RM; Liegler T; Defechereux P; Kashuba AD; Taylor D; Abdel-Mohsen M; Deese J; Fransen K; De Baetselier I; Crucitti T; Bentley G; Agingu W; Ahmed K; Damme LV
AIDS; 2015 Jan; 29(3):331-7. PubMed ID: 25503265
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
11. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
14. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
15. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
16. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF;
N Engl J Med; 2015 Dec; 373(23):2237-46. PubMed ID: 26624850
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
[TBL] [Abstract][Full Text] [Related]
18. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
20. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Kabbara WK; Ramadan WH
J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
